CVT-E002 stimulates the immune system and extends the life span of mice bearing a tumor of viral origin.

Abstract

The present study evaluated the dose-related effects of CVT-E002, a proprietary extract of Panax quinquefolius (CV Technologies Inc., Edmonton, AB), in the treatment of a tumor of viral origin, that is, erythroleukemia, in mice. Three treatments including ingestion of 2, 40, and 120 mg/d were compared. The study revealed that the dose of 40 mg/d was particularly effective in stimulating cells mediating nonspecific immunity and extending the life span of tumor-bearing mice. This study represents the first in vivo demonstration of the anticancer efficacy of CVT-E002 in an animal model. CVT-E002 treatment significantly elevated the absolute numbers of natural killer cells and monocytes and reduced the number of tumor cells in the bone marrow and spleen. This study has shown that (1) approximately 30 to 50% of tumor-bearing mice administered CVT-E002 at a dose of 40 mg/d achieved a significantly extended life span, and (2) dosage is critical in producing these ameliorative effects.

• Authors: Sandra C Miller, Danielle Delorme, Jacqueline J Shan
• Journal: Journal of the Society for Integrative Oncology (J Soc Integr Oncol) Vol. 7 Issue 4 Pg. 127-36 ( 2009) ISSN: 1715-894X [Print] Canada
• PMID: 19883528 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• COLD-fX
• Plant Extracts

Topics

• Animals
• Bone Marrow (drug effects, immunology)
• Bone Marrow Cells (drug effects, immunology)
• Friend murine leukemia virus
• Killer Cells, Natural (drug effects)
• Leukemia, Erythroblastic, Acute (drug therapy)
• Leukemia, Experimental
• Male
• Mice
• Mice, Inbred DBA
• Monocytes, Activated Killer (drug effects)
• Panax
• Plant Extracts (administration & dosage, pharmacology)
• Specific Pathogen-Free Organisms
• Spleen (cytology, drug effects, immunology)
• Tumor Cells, Cultured